Activating the NFE2L1-ubiquitin-proteasome system by DDI2 protects from ferroptosis: Mechanistic insights and research implications

Study Background and Research Question

Ferroptosis is an iron-dependent, non-apoptotic cell death process characterized by extensive lipid peroxidation and loss of plasma membrane integrity. Its unique molecular signature—distinct from apoptosis and necrosis—has positioned ferroptosis at the center of research into neurodegenerative disorders, cancer, and therapy resistance. A critical determinant of ferroptosis sensitivity is the balance between oxidative stress and cellular defense systems, notably the glutathione peroxidase 4 (GPX4) pathway, which utilizes glutathione to detoxify lipid peroxides. While the direct inactivation of GPX4 (e.g., by RSL3) reliably triggers ferroptosis, the role of adaptive protein homeostasis mechanisms, particularly the ubiquitin-proteasome system (UPS), has remained incompletely understood.

The reference study (Ofoghi et al., 2025) addresses a fundamental question: How does the NFE2L1-UPS axis, regulated by the protease DDI2, contribute to ferroptosis resistance, and what are the consequences of pharmacologically targeting this pathway?

Key Innovation from the Reference Study

This work delineates a feedback loop in which DDI2-mediated processing of the transcription factor NFE2L1 is essential for reconstituting proteasome capacity during ferroptotic stress. The authors reveal that ferroptosis-inducing conditions cause a decline in proteasome activity and accumulation of ubiquitylated proteins. In response, NFE2L1—upon cleavage by DDI2—activates transcription of proteasome subunit genes, restoring UPS function and protecting cells from ferroptotic death. Importantly, pharmacological inhibition of DDI2, including by the HIV-1 protease inhibitor Nelfinavir Mesylate, disables this adaptive mechanism, sensitizing cells to ferroptosis. This positions the DDI2-NFE2L1-proteasome axis as a critical cellular safeguard and as a potential pharmacological vulnerability in cancer and other diseases involving ferroptosis.

Methods and Experimental Design Insights

The study employs a suite of unbiased proteomic analyses to map ubiquitylation site changes under ferroptotic stress. RSL3 (a GPX4 inhibitor) is used to induce ferroptosis in cultured cells, followed by assessment of proteasome activity, global ubiquitin conjugate accumulation, and NFE2L1 activation status. Genetic knockout models for DDI2 are constructed to evaluate the necessity of this protease in NFE2L1 activation and ferroptosis resistance. Pharmacological studies include treatment with Nelfinavir Mesylate to inhibit DDI2 and assess cell susceptibility to ferroptosis. The authors integrate immunoblotting, qRT-PCR, and cell viability assays to triangulate mechanistic conclusions.

Protocol Parameters

• Ferroptosis induction (RSL3): Use 1–2 μM RSL3 for 6–24 hours in cultured cells to reliably trigger GPX4-dependent ferroptosis (Ofoghi et al., 2025).
• DDI2 inhibition (Nelfinavir Mesylate): Apply 5–20 μM Nelfinavir Mesylate for 2–24 hours; titrate to balance DDI2 inhibition with minimal off-target toxicity.
• Proteasome activity assays: Measure chymotrypsin-like activity using fluorogenic substrates post-treatment.
• Ubiquitylation profiling: Immunoblot for polyubiquitin (K48/K63 linkages) to assess global UPS disruption.
• Genetic controls: Employ DDI2 knockout or NFE2L1 knockout cell lines for mechanistic specificity.
• Cell viability endpoints: Use CCK-8 or LDH release assays to quantify ferroptotic cell death.

Core Findings and Why They Matter

The central findings can be summarized as follows:

• Ferroptosis impairs proteasome function: Exposure to RSL3 diminishes 26S proteasome activity, resulting in an accumulation of polyubiquitylated proteins.
• NFE2L1 is adaptively activated: In response to proteasomal impairment, NFE2L1 undergoes DDI2-dependent cleavage, enters the nucleus, and upregulates proteasome subunit gene expression—restoring protein degradation capacity.
• DDI2 is essential for this adaptation: Cells lacking DDI2 fail to activate NFE2L1 after ferroptotic stress, accruing excessive ubiquitylated proteins and exhibiting heightened sensitivity to ferroptosis.
• Pharmacological inhibition of DDI2 sensitizes cells to ferroptosis: Treatment with Nelfinavir Mesylate, a known HIV-1 protease inhibitor that also targets DDI2, recapitulates the effects of DDI2 genetic loss, promoting ferroptotic cell death under stress.

These findings highlight a previously underappreciated adaptive circuit by which cells counteract ferroptotic injury. The DDI2-NFE2L1-proteasome axis maintains protein quality control under oxidative stress, and its disruption—genetically or pharmacologically—renders cells more susceptible to ferroptosis. This has direct implications for understanding drug resistance in cancer (where ferroptosis evasion is a concern) and for designing combination therapies that exploit this vulnerability.

Comparison with Existing Internal Articles

Several recent resources bridge the study of HIV-1 protease inhibitors with ferroptosis modulation. For example, "Nelfinavir Mesylate: Expanding HIV-1 Protease Inhibition to Ferroptosis Research" explores the dual application of Nelfinavir Mesylate in both antiretroviral and ferroptosis-focused workflows, highlighting its utility as a research tool for dissecting protein homeostasis mechanisms. Similarly, "DDI2-NFE2L1-Proteasome Axis Regulates Ferroptosis Sensitivity" provides a focused synthesis on how DDI2-dependent NFE2L1 activation is critical for cellular defense against ferroptosis, echoing the main findings of the reference study. These articles contextualize the practical integration of HIV-1 protease inhibitors such as Nelfinavir Mesylate into ferroptosis research protocols, supporting robust experimental design and data interpretation.

Compared to these reviews, the present reference study provides direct mechanistic evidence, employing genetic and pharmacological approaches to dissect the DDI2-NFE2L1-proteasome feedback loop in ferroptosis. It moves beyond general association, demonstrating causality and the translational potential of targeting this axis in disease models.

Limitations and Transferability

While the study delivers substantial mechanistic insight, several limitations merit attention. Most experiments are performed in cultured cell lines, which, while tractable, may not capture the full complexity of tissue-level ferroptosis responses in vivo. The pharmacological specificity of Nelfinavir Mesylate for DDI2 versus other aspartyl proteases remains an open question, and off-target effects at higher concentrations cannot be excluded. The generalizability of findings across different ferroptosis triggers (beyond RSL3) or in diverse cell types requires further validation. Finally, while the DDI2-NFE2L1 axis is shown to protect against ferroptosis, its role in other regulated cell death pathways was not systematically interrogated and warrants future exploration.

Why this cross-domain matters, maturity, and limitations

The intersection of antiviral drug research and cell death biology—exemplified by repurposing Nelfinavir Mesylate, a clinically established HIV-1 protease inhibitor, as a DDI2 modulator in ferroptosis workflows—offers unique translational leverage. This cross-domain approach is supported by robust mechanistic evidence in the reference study and by emerging literature, but its clinical maturity for non-HIV indications remains preliminary. Researchers should be cautious in extrapolating findings to in vivo or therapeutic contexts pending further validation.

Research Support Resources

For investigators aiming to replicate or extend these findings, Nelfinavir Mesylate (SKU A3653) is available as a potent, orally bioavailable HIV-1 protease inhibitor with documented utility in both antiretroviral and ferroptosis research workflows. Its inhibitory activity against DDI2, as demonstrated in the reference study, makes it a valuable tool for dissecting the NFE2L1-UPS axis and exploring ferroptosis sensitization. For protocol design, troubleshooting, and further discussion of quantitative benchmarking, researchers may also consult this scenario-driven guide on Nelfinavir Mesylate’s application in cell viability and protease inhibition assays.